Join us Friday to learn more about the announcement


To view this email online, paste this link into your browser:
[link removed]





DONATE ([link removed])

Cystic Fibrosis Foundation
4550 Montgomery Ave, Suite 1100N
Bethesda, Maryland 20814

www.cff.org ([link removed])

Dear Friend,

On Monday, we shared the exciting news that the FDA has approved TRIKAFTA™ ([link removed]) for people with cystic fibrosis age 12 and older who have at least one copy of the F508del mutation. With the introduction of this triple-combination modulator, more than 90 percent of people with CF could eventually have a highly effective therapy for the underlying cause of their disease.

The CF community is invited to a Community Q&A Webinar on Friday, October 25 from 4:00 - 4:30 pm ET ([link removed]) to learn more about this important milestone.

REGISTER FOR THE WEBINAR ([link removed])

We will be joined by Michael Boyle, MD, SVP of Therapeutics Development, Mary Dwight, SVP of Policy and Advocacy, and Bruce Marshall, MD, SVP of Clinical Affairs, who will discuss the research behind the triple combination therapy, questions around access, and how this breakthrough is expected to impact the health of those approved for the drug.

We hope you are able to join us! ([link removed]) If you are unable to watch live, all those who register will receive a link to the webinar recording and an FAQ based on the community’s questions in the days after the event.





4550 Montgomery Avenue, Suite 1100N | Bethesda, MD 20814 US

This email was sent to [email protected].
To ensure that you continue receiving our emails,
please add us to your address book or safe list.

manage your preferences ([link removed])
opt out ([link removed]) using TrueRemove(r).

Got this as a forward? Sign up ([link removed]) to receive our future emails.
email powered by Emma(R)
[link removed]